guidelines for the diagnosis and management of asthma · 2015-04-14 · expert panel report 2:...

of 25 Diagnosis and Management of Asthma 2013 © Copyright MedStar Health, 2013

Guidelines for the Diagnosis and Management of Asthma Clinical Practice Guideline

September 2013

MedStar Health and MedStar Family Choice accept and endorse the clinical guidelines set forth by the National

Heart, Lung, and Blood Institute Expert Panel on Asthma, Expert Panel Report 3 (EPR-3): Guidelines for the

Diagnosis and Management of Asthma – Full Report, 2007. The pre-publication report is available on the web at:

http://www.nhlbi.nih.gov/guidelines/asthma/index.htm#guidelines) with the summary report expected December

2007.

These guidelines provide new guidance for selecting treatment based on a patient's individual needs and level of

asthma control. The EPR-3 builds upon complete asthma guidelines issued in 1991 and 1997 and an update on

selected topics released in 2002. These recommendations are based on the results of evidence-based work in asthma

and represent both results of controlled clinical trials and expert consensus. The guidelines focus on four components

of asthma care: measures to assess and monitor asthma, patient education, control of environmental factors and other

conditions that can worsen asthma, and medications.

The guidelines emphasize that while asthma can be controlled; the condition can change over time and differs among

individuals and by age groups. Thus, it is important to monitor regularly the patient's level of asthma control so that

treatment can be adjusted as needed.

Key features and changes to these four components of asthma care include:

Assessment and Monitoring: EPR-3 takes a new approach to assessing and monitoring asthma by using

multiple measures of the patient's level of current impairment (frequency and intensity of symptoms, low lung

function, and limitations of daily activities) and future risk (risk of exacerbations, progressive loss of lung

function, or adverse side effects from medications). The guidelines stress that some patients can still be at high

risk for frequent exacerbations even if they have few day-to-day effects of asthma.

Patient Education. EPR-3 confirms the importance of teaching patients skills to self-monitor and manage

asthma and to use a written asthma action plan, which should include instructions for daily treatment and ways to

recognize and handle worsening asthma. New recommendations encourage expanding educational opportunities

to reach patients in a variety of settings, such as pharmacies, schools, community centers, and patients’ homes. A

new section addresses the need for clinician education programs to improve communications with patients and to

use system-wide approaches to integrate the guidelines into health care practice.

Control of environmental factors and other conditions that can affect asthma. EPR-3 describes new

evidence for using multiple approaches to limit exposure to allergens and other substances that can worsen

asthma; research shows that single steps are rarely sufficient. EPR-3 also expands the section on other common

conditions that asthma patients can have and notes that treating chronic problems such as rhinitis and sinusitis,

gastroesophageal reflux, overweight or obesity, obstructive sleep apnea, stress, and depression may help improve

asthma control.

Medications. EPR-3 continues the use of a stepwise approach to control asthma, in which medication doses or

types are stepped up as needed and stepped down when possible. Treatment is adjusted based on the level of

asthma control.

http://www.nhlbi.nih.gov/guidelines/asthma/index.htm#guidelines

of 25 Diagnosis and Management of Asthma 2013

© Copyright MedStar Health, 2013

See Product update table at end of document

The stepwise asthma management charts are revised and expanded to specify treatment for three age groups: 0-4

years, 5-11 years, and 12 years and older. The 5-11 age group was added (earlier guidelines combined this group

with adults) as a result of new evidence on medications for this age group and emerging evidence that suggests that

children may respond differently than adults to asthma medications.

The Key Components for Asthma Control

1. Reduce impairment

Prevent chronic and troublesome symptoms (e.g. coughing or breathlessness in the night, in the early

morning, or after exertion).

Require infrequent use (< 2 days per week) of SABA for quick relief of symptoms

Maintain (near) “normal” pulmonary function.

Maintain normal activity levels including exercise and other physical activity and attendance at work or

school).

Meet patients’ and families’ expectations of and satisfaction with asthma care.

2. Reduce Risk

Prevent recurrent exacerbations of asthma and minimize the need for ED visits or hospitalizations

Prevent progressive loss of lung function; for children, prevent reduced lung growth

Provide optimal pharmacotherapy with minimal or no adverse effects

Appendices:

Step Wise Approach For Managing Asthma In Children (0-4 Years Of Age)-

Step Wise Approach For Managing Asthma In Children (5-11 Years Of Age)

Medication Management for Children

Step Wise Approach For Managing Asthma In Youths > 12 And Adults

Medication Management for Youths > 12 and Adults

Product Updates Table

References:

1. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. (1997).NIH publication No.

97-4051. Asthma Education and Prevention Program.

2. Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. (2007). National

Institutes of Health publication number 08-4051. Retrieved September, 2007 from http://www.nhlbi.nih.gov

/guidelines/asthma/asthgdln.htm.

.

Clinical Guidelines are reviewed every two years by a committee of experts in the field. Updates to guidelines

occur more frequently as needed when new scientific evidence or national standards are published.




Product Updates:

Page Item Current Change to

11 Figure 4-4B Budesonide DPI 90, 180, or 200

mcg/inhalation

Budesonide DPI 90 or 180

inhalation

14 Figure 4-4c Albuterol CFC (delete product)

14 Figure 4-4c Pibuterol CFC Autohaler Delete “CFC” from product

description

15 Figure 4-4c Key: CFC, chlorofluorocarbon (delete from key)

20 Figure 4-8a Cromolyn MDI (delete product)

20 Figure 4-8a Nedocromil MDI (delete product)

21 Figure 4-8b Budesonide DPI 90, 180, or 200

mcg/inhalation

Budesonide DPI 90 or 180

inhalation

21 Figure 4-8b Mometasone DPI 200

mcg/inhalation

200 mcg / 400 mcg / >400 mcg

Mometasone DPI 110 or

220 mcg/inhaler

220 mcg/440 mcg/ >440

mcg

21 Figure 4-8b Triamcinolone acetonide (delete product)

23 Figure 4-8c Albuterol CFC (delete product)

23 Figure 4-8c Pibuterol CFC Autohaler Delete “CFC” from product

description

guidelines for the diagnosis and management of asthma · 2015-04-14 · expert panel report 2:...

Documents